OHSU

IRB #

IRB00010122

Title

CBKM120ZUS40: Modular Phase 2 Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 1 - BKM120 for Patients with PI3K-activated Tumors

Principal Investigator

Matthew Taylor

Study Purpose

To find out if BKM120 (the study drug) is safe and has beneficial effects in people with different kinds of cancer.

Medical Condition(s)

Solid tumors (except endometrial cancer, glioblastoma, non-small cell lung cancer, prostate cancer, and breast cancer) and blood cancers (including diffuse large B cell lymphoma and multiple myeloma).

Eligibility Criteria

1. Male or female at least 18 years old.
2. Confirmed diagnosis of select solid tumor or blood cancer.
3. Known to have a PI3K pathway activation (a specific mutation in the tumor).
4. Received at least one prior treatment for recurrent, metastatic, and/or locally advanced disease.
5. Other criteria apply.

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

Until your disease gets worse or you develop unacceptable side effects.

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080

Sponsor

Novartis

Recruitment End

12/31/2014

Compensation Provided

No


Go Back